Condition
Patients With Non-Small Cell Lung Cancer
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 3 (1)
Trial Status
Unknown2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06472245Phase 3RecruitingPrimary
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT04182698Phase 1UnknownPrimary
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC
NCT01193829UnknownPrimary
Development of Circulating Tumour Cell Molecular Diagnostics Using a Novel Microfluidic Device
Showing all 3 trials